Trevi Therapeutics (TRVI) saw a 1.2% increase in after-hours trading following rumors of a potential takeover. Traders pointed to a Betaville "uncooked" alert suggesting that Trevi might be attracting acquisition interest, although the buyer remains unidentified. Trevi's stock has surged nearly 225% this year, and the company is valued at $1.7 billion. The company is also planning multiple phase III trials for chronic cough indications in 2026 as part of its regulatory strategy.
https://www.gurufocus.com/news/3230991/trevi-therapeutics-trvi-rises-on-takeover-speculation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.